TGNA Stock Chart & Stats
€1.32
€0.08(12.28%)
At close: 4:00 PM EST
€1.32
€0.08(12.28%)
Day’s Range― - ―
52-Week Range€0.60 - €1.49
Previous CloseN/A
Volume0.00
Average Volume (3M)2.01K
Market Cap
€202.03M
Enterprise Value€103.55M
Total Cash (Recent Filing)€111.86M
Total Debt (Recent Filing)€2.06M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding278,559,940
10 Day Avg. Volume3,027
30 Day Avg. Volume2,006
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)1.14
Price to Sales (P/S)282.76
P/FCF Ratio-3.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€8.15M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage gives Transgene a stronger balance-sheet foundation than many cash-burning biotechnology peers. Limited debt reduces near-term creditor pressure and preserves flexibility to fund clinical programs, although it does not eliminate the need for future financing.
Specialized Oncology PlatformA focused oncology-immunotherapy platform can support durable value creation if candidates demonstrate clinical benefit. Therapeutic vaccines, individualized approaches, and viral vectors provide differentiated development avenues rather than relying on a single conventional drug program.
Partnering-Based Revenue ModelPartnering can provide non-dilutive or partially non-dilutive support for research and development while sharing commercialization risk. Milestones and royalties also create potential future operating leverage if candidates advance, reducing reliance on internal sales infrastructure.
Bears Say
Persistent Operating LossesPersistent losses show that the current development platform has not yet converted research investment into sustainable earnings. With 2025 profitability deeply negative, Transgene remains dependent on successful clinical progress and future partnering or financing rather than recurring operating income.
Severe Revenue DeteriorationThe sharp revenue contraction highlights the volatility of collaboration-driven income and the absence of a stable commercial product base. Such a small and declining revenue stream provides little support for the existing cost structure, making future milestones or partnerships strategically important.
Ongoing Cash BurnSustained negative operating and free cash flow means clinical development consumes substantial capital without internally generated funding. Continued burn increases dependence on external financing, partnerships, or asset transactions and creates a durable risk of dilution or program prioritization.
Transgene News
TGNA FAQ
What was Transgene SA’s price range in the past 12 months?
Transgene SA lowest stock price was €0.60 and its highest was €1.49 in the past 12 months.
What is Transgene SA’s market cap?
Transgene SA’s market cap is €202.03M.
When is Transgene SA’s upcoming earnings report date?
Transgene SA’s upcoming earnings report date is Sep 24, 2026 which is in 36 days.
How were Transgene SA’s earnings last quarter?
Currently, no data Available
Is Transgene SA overvalued?
According to Wall Street analysts Transgene SA’s price is currently Overvalued.
Does Transgene SA pay dividends?
Transgene SA does not currently pay dividends.
What is Transgene SA’s EPS estimate?
Transgene SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Transgene SA have?
Transgene SA has 278,559,940 shares outstanding.
What happened to Transgene SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Transgene SA?
Currently, no hedge funds are holding shares in DE:TGNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Transgene SA
Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operating as a subsidiary of TSGH SAS, the company maintains a robust pipeline of treatments. This includes TG4050, a therapeutic vaccine in Phase I clinical trials for ovarian cancer and HPV-negative head and neck cancers, and TG4001, another therapeutic vaccine currently in Phase II for HPV-positive cancers. Its oncolytic virus programs feature TG6002, undergoing Phase I/IIa trials for various solid tumors, specifically gastrointestinal adenocarcinomas impacting the stomach, pancreas, and colon, as well as BT-001, an oncolytic virus in Phase I/II for solid tumors. Furthermore, Transgene is progressing TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus targeting solid tumors. The company has established a comprehensive network of partnerships, encompassing strategic collaborations with major players like AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation, alongside licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and additional agreements with Sanofi, BioInvent, and Randox.
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―